Physician profile
Albert J Hicks
NPI 1386808012
$613,367.89
in general payments reported to CMS, 2019-2025
20 companies · $218K in 2025
The $218K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $20K · 2021: $76K · 2022: $63K · 2023: $48K · 2024: $124K · 2025: $218K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $222K · Consulting Fee: $110K · Travel and Lodging: $39K · Food and Beverage: $18K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $221,938.08 |
| Consulting Fee | $110,350.88 |
| Travel and Lodging | $39,239.90 |
| Food and Beverage | $17,880.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $144,931.57 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $119,753.88 | 2021-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $75,581.36 | 2025 | Attruby |
| Cvrx, INC. | $73,108.12 | 2022-2025 | Barostim Neo System |
| Abbott Laboratories | $71,042.34 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Thoratec Heartmate II, Lvas Implant Kit |
| Lilly USA, LLC | $64,755.96 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $34,689.67 | 2020-2022 | |
| Pfizer INC. | $20,945.14 | 2020-2025 | |
| Vifor Pharma, INC. | $2,509.91 | 2020-2021 | |
| Getinge USA Sales, LLC | $1,600.00 | 2022 | |
| Abiomed | $1,232.03 | 2019-2024 | Impella |
| Astrazeneca Pharmaceuticals Lp | $1,205.37 | 2021-2025 | Wainua, Farxiga |
| Ancora Heart, INC. | $793.83 | 2022-2025 | Accucinch |
| Novo Nordisk INC | $633.58 | 2020-2025 | Wegovy, Ozempic |
| Paragonix Technologies, INC. | $160.04 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $119.12 | 2019-2021 | |
| Scpharmaceuticals INC. | $113.40 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.56 | 2022 | |
| Edwards Lifesciences Corporation | $54.35 | 2025 | Sapien 3 Ultra Resilia |
| Endotronix, INC. | $40.66 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.